Mevacor, Pravachol Rx-To-OTC Switches To Be Considered In July
Executive Summary
Rx-to-OTC switch applications for the cholesterol-lowering drugs Mevacor and Pravachol will be reviewed during joint meetings of the Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees July 13 and 14.
You may also be interested in...
Statin OTC Switch Debate Reflects Poorly On Physicians - FDA's Woodcock
The discussion of switching cholesterol agents to over-the-counter status may reflect the failure of physicians to provide adequate counseling to patients, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, told the agency's OTC switch public hearing June 29.
Statin OTC Switch Debate Reflects Poorly On Physicians - FDA's Woodcock
The discussion of switching cholesterol agents to over-the-counter status may reflect the failure of physicians to provide adequate counseling to patients, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, told the agency's OTC switch public hearing June 29.
New Merck Research VP Greene Has Advisory Committee Experience
Douglas Greene, MD, joins Merck Research Laboratories as executive VP-clinical sciences & product development with prior experience serving on FDA's Endocrinologic & Metabolic Drugs Advisory Committee.